Key Highlights
- $111 million Series A funding closed with backers including Revolution Growth, Eli Lilly & Company.
- Development of AI tools for oncology and cardiometabolic disease, aiming to transform precision medicine.
- Two abstracts accepted for publication at AACR 2024, showcasing groundbreaking research.
Source: Business Wire
Notable Quotes
- “The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. We must do better,” – Grant Verstandig, Co-Founder and Executive Chairman at Zephyr AI
- “Our technology…has empirically demonstrated the ability to navigate the intricacies of real-world patient data,” – Dr. Justin Stebbing, Chairman of the Scientific and Medical Advisory Board at Zephyr AI
- “The expansion of our diverse multimodal data resources will accelerate the advancement of Zephyr AI’s algorithms,” – Jeff Sherman, Co-Founder, Interim CEO, and CTO at Zephyr AI
SoHC's Take
The closing of Zephyr AI’s $111 million Series A funding round marks a significant milestone in the field of precision medicine, showcasing the potential of AI to revolutionize healthcare outcomes. With the backing of major investors and the development of advanced data federation tools and machine learning algorithms, Zephyr AI is poised to make substantial contributions to oncology and cardiometabolic disease management. Their focus on improving clinical trial speed and success, coupled with the upcoming presentations at AACR, signals a promising future for AI in healthcare. This initiative not only highlights the growing importance of AI in medical research and treatment strategies but also underscores the critical role of data in understanding and combating complex diseases.
